Stocks
ARK Genomic Revolution ETFARKG
CBOEHealthcareBiotechnology$45.38+0.73%
Price as of · delayed, not real-time
This actively managed ETF focuses on companies poised to benefit from advancements in genomic technologies, including gene editing, molecular diagnostics, and bioinformatics. Investors track ARKG for exposure to disruptive innovation in life sciences, particularly firms developing CRISPR therapies, next-generation sequencing, and precision medicine tools.
Market Cap: $1.1B52W Range: $24.60-$50.53
Congressional Interest in ARK Genomic Revolution ETF (ARKG)
2 members of Congress have disclosed 5 trades in ARK Genomic Revolution ETF (ARKG), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 3 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
5
Unique Politicians
2
Buys
2
Sells
3
Who in Congress Is Trading ARKG?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-03-25 | Dwight Evans | sell | $1K-$15K |
| 2022-03-25 | Dwight Evans | sell | $1K-$15K |
| 2021-11-02 | Dwight Evans | sell | $1K-$15K |
| 2020-10-29 | Dwight Evans | buy | $1K-$15K |
| 2019-09-27 | Francis Rooney | buy | $1K-$15K |